Early diagnosis of transthyretin cardiac amyloidosis | Clinical Research Studies Listing

Recruiting

99 years or below

All

100 participants needed

1 Location

Brief description of study

Disease modifying therapies for ATTR transthyretin cardiac amyloidosis (ATTR-CA) promises to make a previously untreatable disease manageable. In general, cardiac amyloidosis of any type has been shown to be underdiagnosed or diagnosed late in the disease process. Our goal of the study is to identify African American (AA) patients who are carrying the V122I ATTR mutation with mild left ventricular hypertrophy and other patients who might have wild type ATTR (senile amyloidosis) who presented with carpal tunnel syndrome for surgical intervention, or lone atrial fibrillations, or other clinical suspicion. We would like to establish non-invasive methods using cardiac MRI and radionuclide imaging techniques (pyrophosphate technetium scan (PYP) to detect early stage CA infiltration in the heart.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 09 Apr 2021. Study ID: 834188

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).